Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Researchers at the University of Maryland at College Park analyzed data collected by a trained pregnancy counselor at the student health center of a large, public, East Coast university through follow-up telephone calls to 97 women who had received emergency contraceptive pills (ECPs). They aimed to examine the feasibility and usefulness of a telephone follow-up procedure for women who had received ECPs at a university health center as well as the women's experiences after ECP use. 27.8%, 52.6%, 18.6%, 1% of the students asked for ECPs within 12, 13-24, 25-48, and 49-72 hours of unprotected intercourse, respectively. The main circumstances necessitating the need for ECPs were condom breakage (43.8%) and failure to use contraception (33%). 53.7% used a condom during intercourse, either alone or with another contraceptive method. Despite many efforts, the counselor could only reach 67% of the women. The leading source of information about ECPs was a friend (49.2%). 93.4% took the first dose of ECPs within six hours after their clinic visit. All 65 women took Tigan to prevent nausea, but 18.5% did not take it as prescribed. Nausea was the most common side effect (40% after 1st dose and 29% after 2nd dose). Other side effects were rare. All four women (6.2%) who did not bleed after taking ECPs were tested for pregnancy and found to be pregnant. The entire follow-up procedure took 4-6 hours/week (total of 264 calls), which would cost $45-200/week depending on who is doing the follow-up. Many students viewed the telephone call with suspicion and did not want to talk about their ECP experience. These findings suggest that an ECP follow-up telephone call is neither useful nor cost-effective because user compliance was high, there were minimal ECP side effects, and ECPs are effective in preventing pregnancy.
 ...
PMID:Feasibility of a telephone follow-up on use of emergency contraceptive pills in a college health center. 858 38

This manuscript provides a practical summary of guidelines for institution of apomorphine subcutaneous injectable therapy, including patient education, pre-treatment issues, dosage titration and side-effect care. The timing of each injection is crucial if an impending "off" period is to be averted. Patients need to be aware of symptoms of an approaching "off" period, and the injection should be administered at the onset or ideally, in anticipation of an "off" episode. Patients being considered for apomorphine treatment should undergo pre-treatment assessment and optimization of ongoing oral therapy prior to initiation. Education and counseling regarding the benefits of apomorphine can often alleviate this. In addition, and where available, it is beneficial to provide the patient and caregiver(s) with additional written information and videos provided by the manufacturer demonstrating the operation of the pump or pen injection systems. Once a patient has been assessed as being a suitable candidate for apomorphine, an apomorphine challenge is performed to determine responsiveness and guide appropriate dosing, establish an individual dose, and to observe for side effects, such as nausea, postural hypotension, excessive somnolence, or dyskinesia. Three days prior to the challenge, domperidone 20 mg tid or trimethobenzamide (Tigan) 300 mg tid is recommended. Potential side effects include yawning, dopaminergic side effects, such as dyskinesias, nausea, orthostatic hypotension, confusion, hallucinations, somnolence and rarely, hypersexuality or other behavioral disturbances, and skin nodule formation.
 ...
PMID:Practical considerations in the use of apomorphine injectable. 1503 70